Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 45%
Hold 36%
Sell 9%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is a surgical robotics company with a strong focus on advancing patient care. The company has a promising product pipeline with the AquaBeam and HYDROS robotic systems, and a potential market opportunity in treating BPH and prostate cancer. Though there may be near-term challenges with sales force restructuring and reimbursement dynamics, strong capital placements and enthusiasm for the technology suggest potential for long-term growth and success. Financially, the company has demonstrated strong domestic capital placements and high average selling prices, indicating potential for revenue growth and profitability in the future. The company's current stock price may not fully reflect its potential success in the market, making it a potential investment opportunity.

Bears say

PROCEPT BioRobotics is facing challenges with its utilization rates and potential competition in the market, leading to lowered procedure forecasts and a potential impact on revenue growth in the coming years. This, coupled with management's overly aggressive outlook for procedure growth and potential reimbursement changes for Aquablation, could hinder the stock's performance. Additionally, there may be some concerns about the sales initiatives and their potential impact on utilization rates in the long term.

PRCT has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 45% recommend Buy, 36% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Hold based on their latest research and market trends.

According to 11 analysts, PRCT has a Hold consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.